Search

Your search keyword '"Moulton, Brian"' showing total 8 results

Search Constraints

Start Over You searched for: Author "Moulton, Brian" Remove constraint Author: "Moulton, Brian" Topic 111299 oncology and carcinogenesis not elsewhere classified Remove constraint Topic: 111299 oncology and carcinogenesis not elsewhere classified
8 results on '"Moulton, Brian"'

Search Results

1. Supplementary_Table_2 – Supplemental material for Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08–10 trial

2. Supplementary_Table_1 – Supplemental material for Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08–10 trial

3. Supplementary_Table_3 – Supplemental material for Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08–10 trial

4. Supplementary_Table_3 – Supplemental material for Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08–10 trial

5. Supplementary_Table_1 – Supplemental material for Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08–10 trial

6. Supplementary_Methods – Supplemental material for Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08–10 trial

7. Supplementary_Table_2 – Supplemental material for Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08–10 trial

8. Supplementary_Methods – Supplemental material for Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08–10 trial

Catalog

Books, media, physical & digital resources